Beta Bionics

Beta Bionics Receivables

The Accounts Receivable of Beta Bionics (BBNX) as of Nov 22, 2026 is 12.00 M USD. In the previous year, Accounts Receivable was 4.45 M USD — a change of 169.69% (higher).

Receivables

12.00 MUSD

YoY

169.69%

Last updated:

Accounts Receivable of Beta Bionics is 2024 12.00 M USD. Accounts Receivable of Beta Bionics was 2023 4.45 M USD. It decreases by 169.69% higher compared to the previous year.

The Beta Bionics Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2022
0.00 USD
Jan 1, 2023
4.45 M USD
Jan 1, 2024
12.00 M USD
The Beta Bionics Receivables history
YEARReceivablesYoY
12.00 MUSD+169.69%
4.45 MUSD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beta Bionics Stock analysis

What does Beta Bionics do? Beta Bionics, Inc. generates revenue through the sale of its iLet Bionic Pancreas system, which includes the iLet for Adults and iLet for Children variants. The company also offers the Bionic Circle App and iLet Simulator as complementary products. These solutions are designed for patients with Type 1 diabetes, targeting both adult and pediatric segments. The firm is developing a patch pump and a bihormonal configuration of the iLet, though these are not yet commercialized. The iLet Bionic Pancreas utilizes adaptive closed-loop algorithms to autonomously manage insulin dosing without requiring carbohydrate counting, addressing a key need in T1D treatment. The product line is FDA-cleared, providing a regulatory advantage in the medical device market. Beta Bionics focuses on the diabetes management segment, serving patients who require advanced insulin delivery systems. The company's revenue streams are currently derived from the iLet system and its associated digital tools, with future potential from the patch pump and bihormonal configurations once development is complete. The firm's commercial-stage status indicates active sales and market penetration, supported by its FDA-cleared product and targeted patient segments. Beta Bionics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beta Bionics stock

Accounts Receivable of Beta Bionics is 12.00 M USD in 2024.

Accounts Receivable of Beta Bionics changed from 4.45 M USD to 12.00 M USD, representing a 169.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Beta Bionics since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Beta Bionics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Beta Bionics

All Key Metrics — Beta Bionics